Pilot study by Brigham investigators finds that an innovative care-delivery program helped 81 percent of participants achieve blood pressure control in seven weeks
Hypertension, or high blood pressure, is a widespread clinical problem affecting nearly half of all adults. Despite the serious consequences that can result from hypertension, which puts patients at increased risk for heart attacks, strokes and other cardiovascular events, elevated blood pressures often remain untreated or undertreated for years, and the control rate for hypertension hovers at just 50 percent. Seeing opportunities for improvement, innovators and clinicians at Brigham and Women’s Hospital have developed a new home-based, care-delivery program aimed to improve hypertension control rates quickly and at significantly lower cost than traditional, office-based blood pressure programs. The new approach, piloted among 130 participants, helped 81 percent of patients bring their blood pressures under control in, on average, just seven weeks. The results of the pilot study are published this week in Clinical Cardiology.
“This is a striking result, especially given the very short time frame in which control was reached: an average of seven weeks,” said corresponding author Naomi Fisher, MD, director of the Hypertension Service and Hypertension Specialty Clinic at the Brigham. “There are a few notable health care systems that have matched or exceeded this control rate, but most clinical practices do not approach this rate of success.”
To overcome some of the challenges that clinical practices face, Fisher and colleagues combined several innovative strategies to create their program. Enrolled participants each received a Bluetooth-enabled blood pressure device that could automatically transmit the blood pressure measurements patients took at home into their electronic medical records. Patients had easy and frequent access to “patient navigators”–non-physicians who had been trained to use a clinical algorithm developed by hypertension specialists. The program enabled rapid assessment and medication dosage adjustments for the patients.
The pilot was conducted as a prospective cohort study. The team enrolled 130 patients whose blood pressure was uncontrolled (greater than 140/90 mmHg). Patients were recruited from two clinics to test efficacy in two settings: a Brigham primary care clinic (800 Huntington Ave.), and the Brigham’s Watkins Cardiovascular Clinic. All adults were eligible except pregnant women and those with advanced kidney disease. Enrolled patients were given a Bluetooth-enabled blood pressure device and taught how to use it. Patients were instructed to measure their blood pressure at home twice daily in duplicate. Medication adjustments were made every two weeks until home blood pressure was controlled at <135/85 mmHg.
The team’s next step will be to scale up the program to test its generalizability and sustainability. With this approach, the team anticipates significant cost effectiveness and cost savings, in addition to the prevention of cardiovascular events and death from treating hypertension more intensively in men and women.
“The time-honored model of treating hypertension via traditional visits to the doctor is neither effective nor sustainable,” said Fisher. “Development of innovative solutions to manage hypertension effectively and efficiently, and thus reduce the cardiovascular risk burden in larger populations, is critical. Organizations can and should develop and adopt innovative technologies to create sustainable solutions for the control of hypertension.”
The Latest on: Hypertension
via Google News
The Latest on: Hypertension
- PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertensionon January 13, 2020 at 4:33 pm
MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and.
- BRIEF-Tenax Therapeutics Provides Update On Phase 2 Pulmonary Hypertension Clinical Trialon January 13, 2020 at 6:28 am
Tenax Therapeutics Inc: * TENAX THERAPEUTICS PROVIDES UPDATE ON PHASE 2 PULMONARY HYPERTENSION CLINICAL TRIAL * TENAX THERAPEUTICS INC - 24 PATIENTS HAVE BEEN RANDOMIZED IN PHASE 2 PULMONARY ...
- Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trialon January 13, 2020 at 5:38 am
Enrollment Update Tenax is conducting a multi-center, double-blind, placebo-controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with ...
- Disruption of CXCR6 Ameliorates Kidney Inflammation and Fibrosis in Deoxycorticosterone Acetate/Salt Hypertensionon January 10, 2020 at 5:17 am
In summary, our results identify a critical role of CXCR6 in the development of inflammation and fibrosis of the kidney in salt-sensitive hypertension. Chronic kidney disease is a growing public ...
- Hypertension in Indians and impact of salton January 10, 2020 at 2:14 am
Hypertension is the most important risk factor for chronic disease burden across the world. Global burden of diseases study in year 2017 reported high systolic BP as the leading risk factor across the ...
- Livongo Diabetes and Hypertension Solutions Now Available via Higi Smart Stations at Major Retailerson January 9, 2020 at 5:00 am
About Livongo Livongo offers a platform to care for the whole person and empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including ...
- NIH Partners with WellCare and Wellth for New Program that Rewards New York Medicaid Members for Managing Hypertensionon January 8, 2020 at 4:30 am
/PRNewswire/ -- WellCare Health Plans, Inc. (NYSE: WCG) announced today it is working with the National Institutes of Health (NIH) to partner with Wellth ...
- Urinary NT-proBNP as a potential noninvasive biomarker for screening of pulmonary hypertension in preterm infants: a pilot studyon January 7, 2020 at 4:37 am
This pilot study aimed to determine the feasibility of urinary NT-proBNP (NT-proBNP) as a potential noninvasive screening marker for pulmonary hypertension (PH). Thirty-six patients were included in ...
- Hypertension Causes: What Is The Relation Between High Blood Pressure And Long Working Hours? Know Some Prevention Stepson January 7, 2020 at 3:34 am
Keep a constant check on your blood pressure numbers Make necessary changes to maintain healthy blood pressure numbers Long working hours is also associated with high blood pressure High blood ...
- Berry juice beneficial for patients suffering from hypertension: Studyon January 6, 2020 at 10:35 pm
A recent research has concluded that consuming berry juice for the long-term might help hypertension patients for lowering blood pressure. The study also suggested that the same also helps in ...
via Bing News